Covid-19 Series July 2020

  • July 1.png
  • July 2.png
  • July  3.png
  • July 4.png
  • July 5.png
  • July 6.png
  • July 7.png
  • July 8.png
  • July 9.png
  • July 10.png

Our team went through many data sources and prepared COVID-19 and the life sciences industry deck.

To download the deck, here is the link

Topics covered in the deck: 

  • Basics about SARS-CoV-2 & COVID-19: 


•Origin: Possibly in wet animal market in Wuhan, China

•Disease: Coronavirus disease 2019 (COVID-19)

•Cause: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

•Strain: Same virus as SARS-CoV-1, which affected 8,000 people in 2002-03

•DNA Study (Feb-2020): 96% DNA match between bat coronavirus and human suggests link to humans is not direct but through intermediate host

•Target: Upper respiratory tract and can spread to lungs

Transmission & Mechanism

•Enters through nose, mouth, or eyes

•Attaches to cells in the respiratory tract producing a protein called ACE2

•It fuses with the cell and releases the RNA

•The hijacked infected cell will produce proteins based on the “instructions” from the virus’ RNA

•Each infected cell can release millions of copies of the virus before dying


•Virus appears highly transmissible - Average patient infects 1.6 to 2.4 other people

•Affects older patients and fatality rate in the 70s is 3-4 times larger than the average

Men are twice more likely to get infected than women

COVID-19 Industry Impact Heatmap

  • Key impacts of the COVID-19 pandemic on Life Sciences Companies:

The Slowdown of Economic Growth

Demand Disruption

Operations Disruption

Impact on Regulatory Function

Increase in Costs

Product Launch Delays

Virology Science

Clinical Trial Delays

  • Short Term Action Plan for Life Sciences Companies

Secure Core Operations

Prioritize Clinical Trials

Revise Operating Model

Reduce Dependencies/Risks

  • Long Term Action Plan for Life Sciences Companies

Re-evaluate Strategy Plans

Revise Operating Model

Boost Commercial Activities

Acquisitions & Divestments

Enterprise Risk Management

Resume R&D Activities

Ensure Business Continuity

  • How can London Strategy help?

Re-evaluate Strategy Plans

Revise Operating Model

Boost Commercial Activities

Acquisitions & Divestments

Enterprise Risk Management

Operational Improvement

Ensure Business Continuity

  • The response of the Life Sciences Industry

1.     Diagnostics

Diagnostic Testing
The most pressing and immediate need in the battle against COVID-19

2.     Treatments

Treatment Development
 Pharma companies and biotechs are racing to develop an effective treatment for the COVID-19

3.     Vaccine

 Life Sciences companies are ratcheting up their efforts with accelerated schedules for creating new vaccines

  • Charts & Insights

Daily Deaths per Day by Country and Region. The death toll is on the rise once again

Mapping the Covid-19 outbreak. The pandemic spreads incredibly quickly between people. More than 10m people infected in appr. 6 months

Covid-19 situation in Europe & US

Comparison of Tests, Cases and Deaths

The Disease Progression

The Top 10 Countries in Reported Covid-19 deaths per Capita

Death rates 2020 vs Historical Averages by Country

Death rates 2020 vs Historical Averages by Urbans

Total COVID-19 tests per 1,000 vs. GDP per capita

Comparison of Tests vs Cases

Comparison of Median Age and Death Rate

The Countries with Critical Care Beds vs Active Cases

EU5 Summary: Hospital systems and COVID-19 testing

Covid-19 Major Events in Global

Timeline of US Government Responses to Covid-19

Timeline of EU5 Government Responses to Covid-19

Reopening Trends by Country

Reopening Trends of U.S

Reopening Trends by Geographies

  • Details of the Virus

Basics about SARS-CoV-2 & COVID-19

Anatomy of the Virus: SARS-CoV-2

Covid-19 Transmission & R0 Reproductive Number

Cellular Pathogenesis of the Virus: SARS-CoV-2

Covid-19 Disease Progression and Multi-Organ Injuries

Three Clinical Phases of Covid-19 Infection and Disease Progression

Almost 90% of Covid-19 Hospital Admissions involve Comorbidities

Potential Therapeutic Targets for SARS-CoV-2

History of Pandemic